December 2022 Conference
Founded in 2020 and headquartered in San Diego, California, Alyra Therapeutics is developing proprietary protein-protein interaction drugs that block the binding of ras oncogene small GTPases to their effectors. Our focus is on the CDC42 family of GTPases, specifically the CDC42 and RHOJ proteins. Using a platform comprising proprietary molecular dynamics methods coupled with protein-protein interaction assay workflows, Alyra has developed several classes of compounds that selectively block the interactions between these GTPases and a key effector, p21 activated kinase 1 (PAK1), without blocking the interactions between GTPases such as RAL and RAC1 and their effectors. Our lead clinical candidate is ALY101, a PAK1 inhibitor which binds to a common motif on the CDC42 and RHOJ GTPases, preventing their ability to bind to and activate PAK1 and its downstream targets, including the MEK and ERK kinases. ALY101 shows significant potential as an adjunctive therapy used in conjunction with targeted therapies and immune-oncology drugs to expand the therapeutic indices of these drugs, increasing safety, efficacy and patient compliance, especially for products with serious safety and tolerability issues that limit their use.
Building on the foundational work of Bectas’ scientific team with world-class expertise in cancer, immunology, drug
discovery and clinical trials, Bectas Therapeutics will bring dynamic precision and human insight to
develop drugs that can overcome a major resistance mechanism mediated by myeloid suppression cells.
Myeloid derived immune suppression could account for over 50% of non-responders to current T-cell
checkpoint inhibitors, representing an addressable market of over $10 billion per annum.
Bespoke is a cellular immunotherapy start-up built-upon NIH and NSF grant funding, a robust B-cell gene editing patent portfolio, and a leadership team composed of cell therapy product development experts. Bespoke is developing proprietary human B-cell non-viral genome engineering and synthetic biology technology platforms as well as innovative engineered B-cell therapeutic products for patients at high risk of relapse or already with metastatic solid tumor cancers. Central to our technologies and product candidates is engineering to create B-cells that only express and secrete immunomodulatory and anticancer protein payloads (e.g., antibodies and interleukins) after stimulation of engineered B-cell receptors by a specific tumor-associated antigen. This B-cell receptor “on-switch” and actuated (i.e., inducible) payload delivery focuses therapy at sites of active disease and prevents dose-limiting and serious systemic off-tumor toxicity. Current pre-clinical research and process development will support an IND for a first-in-human study of autologous B-cell therapeutics in women with advanced breast cancer.
Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
BlueSky Immunotherapies is a European clinical stage life science firm, developing its interferon inducing vector delNS platform against solid cancers & infectious and allergic diseases. The company is in a phase 1 clinical trial against HPV16 induced cervical cancers and lesions and has successfully reached the primary endpoints safety and tolerability. In addition, BlueSky can present excellent efficacy data from this clinical trial. BlueSky Immunotherapies has started reach-out to investors for a Series A financing round of $15m-20m to carry out subsequent clinical trials phase II.
Canget is a biotech and biopharma company spun off from Roswell Park Cancer Institute (Buffalo, NY). Canget’s technology has taken 7 years and $3M funds from federal, public and private foundations to develop its current IP portfolio. Canget focuses on development of novel (low toxic, highly effective and cancer-targeting) anticancer agents.
The mission of CasInvent Pharma is to bring new therapeutic options for the treatment of selected leukemias to market. We are developing highly selective small molecule inhibitors of casein kinase I (CK1), and our main development program is focused on the identification of new drugs for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor CAR-T cell therapeutics with greater efficacy against solid tumors and superior safety. Co-founded by renowned synthetic biologist, Professor Christina Smolke, of Stanford University, Chimera leverages the combination of synthetic biology and immunotherapy, to widen therapeutic windows, expand treatment to cancers with unmet needs and create therapies that restore and maintain patient dignity. Chimera’s differentiated RNA based technologies enable conditional, real-time control over CAR-T solving the critical challenges of safety and potency while extending persistence and efficacy.
Curadigm is a French early-stage nanotechnology company dedicated to improving outcomes for patients by shifting the therapeutic delivery paradigm. Curadigm’s Nanoprimer technology is designed to transiently occupy the liver pathways involved in the clearance of nanomedicine-based therapeutics in order to increase their blood bioavailability while decreasing unintended off-target effects, specifically liver toxicity. The Nanoprimer technology has been validated in combination with different products including nucleic acid-based therapeutics.
Elpis Biopharmaceuticals is engineering and developing multifunctional immunotherapies, which modulate disease biology with precision and safety to overcome cancer resistance. Through its proprietary mRNADisTM antibody discovery and mSCAFoldTM protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers
Enterome is a clinical stage company developing off-the-shelf, transformational cancer treatments targeting all tumor types. Ongoing Phase 2 trials for our most advanced program EO2401 have shown promising efficacy in recurrent glioblastoma and adrenal malignancies and good safety in more than 130 patients. Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T-cells, overcoming the immune tolerance to self-antigens. With 5 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bed”. In addition to OncoMimics™ programs, Enterome has also established partnerships with Takeda and Nestlé Health Science in IBD and food allergy.
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis.
illumiSonics develops, patents and commercializes PARS® advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Founded in 2014, illumiSonics is a privately held medical device company with offices and R&D facilities Waterloo, ON, Canada. The company's executive team of medical device leaders holds an excellent track record of successfully building companies and improving outcomes for clinicians and patients. The technical R&D teams are the pioneers in PARS technology. illumiSonics works with market leading partners to develop systems for specific applications.
Leapfrog Bio is developing targeted therapies for cancers driven by genetic mutations that cannot be treated with conventional approaches. Our advanced pharmacogenomic approach yields novel insights into the biology of these cancers and simultaneously identifies small molecule compounds to effectively treat them. Our goal is to rapidly develop these compounds as genetically targeted therapies for cancer patients with high unmet medical needs.
Link is a developer of next-generation T-cell engaging therapies designed to treat cancer. The company engineers novel, highly developable immunotherapies with both greater selectivity for tumor over normal tissue and more complete T-cell activation, enabling superior safety profiles and more durable cancer patient responses.
The name of our company, Malignant Tumor Treatment Technologies (M.T.3), reflects our desire to continue researching and providing treatment techniques for malignant tumors. Our current core product is a compound derived from marine organisms. This compound is expected to be a novel radiosensitizer because it shows radiosensitizing effects even at low doses, and has low degrees of toxicity and other side effects. We are beginning to explore human medicine applications as we believe our compounds can be fully utilized in such fields.
Nami Therapeutics Corp (’Nami’) is a startup company based in Storrs, CT and currently in the Technology Incubation Program at the University of Connecticut. Nami is developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Nami (which mean ‘nano’ in Mandarin) is using technologies licensed from the University of Connecticut and the University of North Carolina. The Nami team is comprised of Xiuling Lu and Michael Jay, academics with over 50 years of collective experience in the drug delivery field, Ruobing Xia, who has 20+ years of experience in big pharma managing multi-million dollar product launches, and David Worthen, an experienced scientist and entrepreneur with product development, regulatory affairs, and management experience in both industry and academia.
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of many types of cancers, producing durable therapeutical efficacy in advanced- stage tumors. Nonetheless, most cancer patients do not benefit from these therapies. Neomics is developing novel Immune Checkpoint Switching T (ICS T) cell therapy to extend the immunotherapy benefit to patients far and beyond.
NuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a Phase IIa trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF).
Olive Healthcare is a digital healthcare and medical diagnostic devices company. It is focused on abdominal fat scanning and breast cancer diagnosis, using nonradiative and noninvasive near infrared (NIR) technology, artificial intelligence (AI) algorithms, and big data processing for a customized medical service.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways.
Propelle is developing novel biopharmaceuticals and nucleic acid components for unmet medical challenges in targeting early inflammation within the tumor microenvironment to rebalance the immune system and allow the immunity cycle to reduce, shrink or eliminate the tumor by itself.
Revere is a Boston-based, oncology-focused biotech company led by an experienced biopharma team. We are the leaders in developing Rac1 and other Rho (RAS homologous) GTPase inhibitors for treating cancer. Our proprietary platform for identifying small molecule Rac1 inhibitors is unique in the industry and is enabling development of a drug pipeline to address areas of high, unmet needs for cancer patients. We expect to designate our first development candidate in 2023 and file an IND in 2024.
Savor Health is a precision nutrition company that applies the science of nutrition to the optimization of the treatment of cancer and other complex medical conditions to improve health outcomes and reduce cost of care. Through a proprietary expert Platform designed to replicate the logic and knowledge of registered dietitians (“RDs”), Savor Health’s virtual Triage Nurse Function determines patient appropriateness for RD support and triages them to their medical provider or to the Company’s virtual Dietitian-on-Demand (Ina®) who provides 24/7 “on demand” evidence-based nutrition support via SMS text. Launched with pharma clients in 2019 for chemotherapy and immunotherapy symptom self management to improve adherence to their therapies, the Company's market leading results include 65% engagement, 70% utilization, 83% satisfaction and a robust, rapidly growing database of PRO and other real world data.
SmartBreast Corp. is privately held with headquarters near Pittsburgh and offices in Los Angeles and Taipei, Taiwan (eveclearscan.com and smartbreast.com are under construction). It is a subsidiary of privately held EVO WorldWide, LLC (evo-worldwide.com) that distributes MBI globally. SmartBreast was founded in 2019 by Bradley Patt, PhD (Board Chair, Los Angeles), Prof. Chin-Tu Chen, PhD (Board Vice-Chair, Chicago), and James Hugg, PhD (CEO, Pittsburgh), each of whom has 30+ years' experience in medical imaging. SmartBreast manufactures molecular breast imaging (MBI) scanners for dense breasts under the brand name EVE CLEAR SCAN™, which along with SmartBreast™, EVE SCAN™, and the EVE owl logo are trademarks of SmartBreast Corporation.
Starpax Biopharma Inc. has developed a novel Precision 3D Guidance Therapy of Magnetodrones™ in tumours. Magnetodrones™ are unique medication-bearing bacteria, developed by Starpax™, that are sensitive to magnetic fields. They deliver the medication into the mass of the tumour, without allowing the medication to circulate in the bloodstream. At the same time, the Magnetodrones™ saturate hypoxic areas where cancerous cells are difficult to reach with other treatments. Magnetodrones are injected directly into the tumour and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak™ prevents the Magnetodrones™ from leaving the tumour and guides them in 3D with special magnetic fields.
SynDevRx is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. that is leading the research and development of treatments that address the interactions between cancer and dysregulated metabolic hormones. – i.e., metabo-oncology. Obesity, pre-diabetes and type 2 diabetes are known to worsen certain cancer patients’ prognoses, but oncologists have no specific tools to treat systemic or treatment-induced metabolic complications, except for diet and exercise. SynDevRx is initiating a series of proof-of-concept clinical studies of its drug candidate evexomostat (SDX-7320) to show that improving these hormones together with effects on angiogenesis and the tumor micro-environment will result in better patient outcomes, thereby establishing a new and complementary treatment paradigm for tens of thousands of cancer patients.
Tactical Therapeutics Inc (“TTI”) is a privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO)(Pravitinib(TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets.
Thrive Bioscience’s instruments and software provide automated imaging and analytics of live cells and tissues for research and drug discovery. Thrive instruments automatically build extensive databases of terabytes of time-series images at 100 focal planes of all the cells in all the wells in cell culture plates.
TibaRay is an early stage company developing a new Radiation Therapy system that will treat cancer patients in a fraction of a second, resulting in dramatically reduced collateral damage to normal tissue leading to better outcomes. The well-patented enabling technological breakthroughs came out of the SLAC National Accelerator Lab and Stanford University Healthcare and uniquely position TibaRay to disrupt this $7B market by curing cancer in a FLASH.
Vetigenics is a clinical stage animal health biotech devoted to developing species specific cancer immunotherapies to improve and extend the lives of pets and by doing so, expand novel cancer treatment options for their humans. The company’s CANIBODY™ Platform technology utilizes a proprietary, entirely canine phage display platform together with unique panning techniques to rapidly isolate CANIBODIES™ (single chain variable fragments or scFvs) to any target antigen. Once selected, CANIBODIES™ can be easily formatted into a preferred therapeutic such as full-length monoclonal antibodies (mAbs), CAR-T or bi-specific antibodies. CANIBODIES have shown high affinity, good developability and functional characteristics with little to no engineering and once formatted, can be used directly in canine clinical studies. Results to date in canine studies demonstrate excellent safety, good biodistribution and lack of immunogenicity. Strategic partners include NCI, Merck Animal Health and a 2nd Major Animal Health Pharma, several academic research partnerships.